Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent

Publisher： Karger

E-ISSN： 1421-9832|230|4|347-353

ISSN： 1018-8665

Source： Dermatology, Vol.230, Iss.4, 2015-02, pp. : 347-353

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

By  

Dermatology, Vol. 221, Iss. 2, 2010-07 ,pp. : 172-178

Karger

Access to resources Recommend Favorite

Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension

By  

Dermatology, Vol. 222, Iss. 3, 2011-04 ,pp. : 250-255

Karger

Access to resources Recommend Favorite

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

By  

Dermatology, Vol. 225, Iss. 4, 2013-01 ,pp. : 326-332

Karger

Access to resources Recommend Favorite

Impact of Adalimumab on Symptoms of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A Pooled Analysis of Randomized Clinical Trials

By  

Dermatology, Vol. 220, Iss. 1, 2009-11 ,pp. : 1-7

Karger

Access to resources Recommend Favorite

Mild Cognitive Impairment in Patients with Moderate to Severe Chronic Plaque Psoriasis

By  

Dermatology, Vol. 228, Iss. 1, 2014-01 ,pp. : 78-85

Karger

Access to resources Recommend Favorite